Pharmacogenetics and cancer therapy

Pharmacogenetics is the study of how genetic variations affect drug response. These variations can affect a patient's response to cancer drugs, for which there is usually a fine line between a dosage that has a therapeutic effect and one that produces toxicity. Gaining better insight into the genetic elements of both the patient and the tumour that affect drug efficacy will eventually allow for individualized dosage determination and fewer adverse effects.

[1]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Lilleyman,et al.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.

[3]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[4]  J. Hayes,et al.  Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. , 1995, Free radical research.

[5]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[6]  P. Padfield,et al.  Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. , 1998, Journal of cardiovascular pharmacology.

[7]  J. Seidegård,et al.  The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. , 1997, Environmental health perspectives.

[8]  A. Chango,et al.  A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. , 2000, Molecular genetics and metabolism.

[9]  F Demard,et al.  Population study of dihydropyrimidine dehydrogenase in cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[11]  M. Pike,et al.  Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. , 2001, Cancer research.

[12]  S. Higuchi,et al.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.

[13]  W. Hiddemann,et al.  Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities , 2000, Leukemia.

[14]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[15]  G. Peters,et al.  A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance* , 1998, The Journal of Biological Chemistry.

[16]  B. Ketterer.  Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. , 1988, Mutation research.

[17]  D. Nebert,et al.  Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. , 1990, Trends in genetics : TIG.

[18]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[19]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[20]  M. Ratain,et al.  Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital , 1997, Cancer Chemotherapy and Pharmacology.

[21]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[22]  M. Relling,et al.  Thioguanine substitution alters DNA cleavage mediated by topoisomerase II , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  M. Schrappe,et al.  Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. , 2000, Blood.

[24]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[25]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[26]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[27]  M. Rietschel,et al.  Dopamine D3 receptor variant and tardive dyskinesia , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[28]  F. Behm,et al.  Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia , 1998, Leukemia.

[29]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[30]  R. Matthews,et al.  Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification , 1994, Nature Genetics.

[31]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[32]  L. Hutchins,et al.  Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. , 2000, Cancer research.

[33]  S. Liggett.  The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. , 2000, The Journal of allergy and clinical immunology.

[34]  M. Durán,et al.  Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[35]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[36]  M. Relling,et al.  High incidence of secondary brain tumours after radiotherapy and antimetabolites , 1999, The Lancet.

[37]  P. Hopkins,et al.  Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.

[38]  D W Nebert,et al.  Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. , 1996, DNA and cell biology.

[39]  P. Verpillat,et al.  Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine , 2001, Leukemia.

[40]  G. F. Sullivan,et al.  Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. , 2000, The Journal of clinical investigation.

[41]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[42]  潘紀良.  Transfection of Glutathione S-Transferase(GST)-π Antisense Complementary DNA Increases the Sensitivity of a Colon Cancer Cell Line to Adriamycin,Cisplatin,Melphalan and Etoposide(グルタチオンSトランスフェラーゼ(GST)-πのアンチセンス[c]DNAは大腸癌細胞株のアドリアマイシン、シスプラチン、メルファラン、エトポシドの感受性を増加させる) , 1996 .

[43]  D. Waxman,et al.  Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. , 1997, Cancer research.

[44]  C. Bloomfield,et al.  Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect , 1996, The Lancet.

[45]  E. Raymond,et al.  Metabolism of Irinotecan ( CPT-11 ) by CYP 3 A 4 and CYP 3 A 5 in Humans 1 , 2000 .

[46]  J. Buckley,et al.  Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  E. Sacchi,et al.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. , 1998, The New England journal of medicine.

[48]  C. Ulrich,et al.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. , 2001, Blood.

[49]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[50]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[51]  W. J. Spillman.  INHERITANCE OF COLOR COAT IN SWINE. , 1906, Science.

[52]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[53]  G. Tucker,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE , 1977, The Lancet.

[54]  M. Relling,et al.  Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. , 2001, Cancer research.

[55]  M. Dolan,et al.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.

[56]  T. Rebbeck.  Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4 , 1999 .

[57]  A. Paulussen,et al.  Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. , 2000, Pharmacogenetics.

[58]  C. Pui,et al.  Acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[59]  R. Weinshilboum.  Human pharmacogenetics: Introduction. , 1984, Federation proceedings.

[60]  H. McLeod,et al.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. , 1996, The Journal of clinical investigation.

[61]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[62]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[63]  M. Relling,et al.  Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. , 1997, Blood.

[64]  Cancer, genomics, and the National Cancer Institute. , 1999 .

[65]  J. Schornagel,et al.  Resistance to methotrexate due to gene amplification in a patient with acute leukemia. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[67]  P. Kwok,et al.  High-throughput genotyping assay approaches. , 2000, Pharmacogenomics.

[68]  F. Behm,et al.  Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies , 2000, Leukemia.

[69]  U. Meyer,et al.  Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P‐450IID1 , 1990, Clinical pharmacology and therapeutics.

[70]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Vreken,et al.  Nomenclature for human DPYD alleles. , 1998, Pharmacogenetics.

[73]  M. Eichelbaum,et al.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. , 1995, British journal of clinical pharmacology.

[74]  D. Farquhar,et al.  Mutagenic consequences of the incorporation of 6-thioguanine into DNA. , 1997, Biochemical pharmacology.

[75]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[76]  L. Peltonen,et al.  A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. , 2000, Genome research.

[77]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[78]  C. Morton,et al.  Proficient metabolism of irinotecan by a human intestinal carboxylesterase. , 2000, Cancer research.

[79]  Martin R. Johnson,et al.  Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  M. Relling,et al.  Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. , 1996, Pharmacogenetics.

[81]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[82]  P. Wilson,et al.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations. , 1999, The New England journal of medicine.

[83]  M. Relling.  Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? , 1996, Therapeutic drug monitoring.

[84]  M. Relling,et al.  Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia , 1997 .

[85]  J. Ritter,et al.  A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. , 1992, The Journal of biological chemistry.

[86]  S. Wrighton,et al.  Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. , 2000, Pharmacogenetics.

[87]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. , 1993, Cancer research.

[88]  D. Thomas.  Design of gene characterization studies: an overview. , 1999, Journal of the National Cancer Institute. Monographs.

[89]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[90]  R. Hauer,et al.  Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. , 1999, Circulation.

[91]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  G. Colditz,et al.  A Polymorphism in CYP 17 and Endometrial Cancer Risk 1 , 2001 .

[93]  R. Schilsky,et al.  Clinical pharmacology of methotrexate. , 1981, Cancer treatment reports.

[94]  M. Boyce-Jacino,et al.  A SNPshot: pharmacogenetics and the future of drug therapy. , 2000, Trends in biotechnology.

[95]  F. Goldwasser,et al.  Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  K D Friedman,et al.  Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes. , 2000, Clinical chemistry.

[97]  J. Sugatani,et al.  The phenobarbital response enhancer module in the human bilirubin UDP‐glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR , 2001, Hepatology.

[98]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[99]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[100]  M. Relling,et al.  Gazing into a crystal ball–cancer therapy in the post-genomic era , 2001, Nature Medicine.

[101]  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999 .

[102]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.

[103]  S. Cohn,et al.  Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[104]  G. Elion.  The Purine Path to Chemotherapy , 1989 .

[105]  佐田 文宏.  CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12 : evidence for an allelic variant with altered catalytic activity , 2000 .

[106]  J. Rastad,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Vitamin D Receptor (VDR) and Parathyroid Hormone Messenger Ribonucleic Acid Levels Correspond to Polymorphic VDR Alleles in Human Parathyroid Tumo , 2022 .

[107]  F. Gonzalez,et al.  Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. , 1995, Trends in pharmacological sciences.

[108]  P. Sonneveld,et al.  MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. , 2001, Blood.

[109]  S. Liggett.  β2-Adrenergic Receptor Pharmacogenetics , 2000 .

[110]  O. Haas,et al.  MDR1 gene expression and treatment outcome in acute myeloid leukemia. , 1991, Journal of the National Cancer Institute.

[111]  A Gouyette,et al.  Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  M. Fukuoka,et al.  Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[114]  M. Waltham,et al.  Intrinsic and acquired resistance to methotrexate in acute leukemia. , 1996, The New England journal of medicine.

[115]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.

[116]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[117]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[118]  T. L. Witt,et al.  Impaired Membrane Transport in Methotrexate-resistant CCRF-CEM Cells Involves Early Translation Termination and Increased Turnover of a Mutant Reduced Folate Carrier* , 1999, The Journal of Biological Chemistry.

[119]  S. Koizumi,et al.  A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  W. Evans,et al.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[121]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[122]  E. Briganti,et al.  Polymorphism of the Vitamin D Receptor Gene and Corticosteroid-Related Osteoporosis , 1999, Osteoporosis International.

[123]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  J. Todd,et al.  Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. , 2000, Genome research.

[125]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[126]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[127]  W. Evans,et al.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.

[128]  G. Colditz,et al.  A polymorphism in CYP17 and endometrial cancer risk. , 2001, Cancer research.

[129]  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.

[130]  G. Giles,et al.  CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. , 2000, Journal of the National Cancer Institute.

[131]  B. Hoogendoorn,et al.  Determination of SNP allele frequencies in pooled DNAs by primer extension genotyping and denaturing high-performance liquid chromatography. , 2001, Journal of biochemical and biophysical methods.

[132]  G. Elizondo,et al.  CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity , 2000, Clinical pharmacology and therapeutics.

[133]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[134]  F. Baas,et al.  Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[135]  M. Eichelbaum,et al.  The genetic polymorphism of sparteine metabolism. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[136]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[137]  F. Vogel.  Moderne Probleme der Humangenetik , 1959 .

[138]  Michael Owen,et al.  Cheap, accurate and rapid allele frequency estimation of single nucleotide polymorphisms by primer extension and DHPLC in DNA pools , 2000, Human Genetics.

[139]  P. Muti,et al.  Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. , 2000, Pharmacogenetics.